SSR3

Across TCGA pan-cancer cohorts, SSR3 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of SSR3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SSR3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SSR3 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

HNSC, KIRC, and BLCA are the cancer types where SSR3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SSR3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+1.098	<.001	12	view →
KIRC	Male	IV	+0.852	<.001	12	view →
BLCA	Male	III,IV	+1.070	<.001	11	view →
LIHC	Male	II,III,IV	+1.265	<.001	9	view →
LUAD	Male	All	+0.628	<.001	8	view →
STAD	All	II,III,IV	+0.670	<.001	6	view →
CHOL	Male	All	+2.018	<.001	5	view →
KICH	Female	II,III,IV	−1.832	<.001	5	view →
COAD	All	II,III,IV	+0.447	.001	5	view →
BRCA	All	II,III,IV	+0.265	<.001	4	view →
LUSC	Male	All	+0.430	<.001	2	view →
ESCA	All	All	+0.823	.006	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

SSR3–HNSC

Open the HNSC breakdown →